Neurology, biomanufacturing start-ups bag UK AI funding The first recipients of the UK government's £500 million Sovereign AI fund have been announced, including two life sciences-focused start-ups.

The first recipients of #funding under the #UK government's £500 million #SovereignAI programme have been announced, intended to help nurture promising, home-grown #startups.

pharmaphorum.com/news/neurolo...

FDA delays decision on Sanofi's subcutaneous Sarclisa The FDA has extended its review of a new version of Sanofi's multiple myeloma Sarclisa that could help narrow the gap with arch-rival Darzalex.

The #FDA has extended its review of a new #subcutaneous formulation of #Sanofi's #multiple ]myeloma therapy #Sarclisa – which has long played second fiddle to Johnson & Johnson's blockbuster rival Darzalex – by three months.

pharmaphorum.com/news/fda-del...

New data build case for Roche's oral BTK drug for MS Roche remains confident in the prospects for its soon-to-be-filed oral BTK drug fenebrutinib for multiple sclerosis, despite safety concerns.

#Roche has said its #oralBTKinhibitor #fenebrutinib could become the first drug in the class to be approved for #multiplesclerosis, after reporting new data from two phase 3 trials.

pharmaphorum.com/news/new-dat...

Pivotal trial of Moderna's H5N1 bird flu jab gets underway The first volunteers in a large-scale trial of Moderna's mRNA-based vaccine against bird flu have received shots in the UK and US.

The first volunteers in a large-scale trial of #Moderna's #mRNA-based #vaccine against #birdflu – long considered to be a #pandemicthreat – have received shots in the #UK and #US.

pharmaphorum.com/news/pivotal...

The #Trumpadministration has extended the duration of a #pilot programme to provide #access to #obesitydrugs through #Medicare, as too few #insurance companies have agreed to sign up.

pharmaphorum.com/news/medicar...

In today’s headlines: pharmaphorum.com/news

#news #pharma #lifesciences #pharmanews #pharmaindustry

#NovoNordisk is planning to move ahead with #regulatory filings for #etavopivat, potentially a first-in-class therapy for #sicklecelldisease, based on positive results in a phase 3 trial.

buff.ly/hI6iav7

A combination regimen for #kidneycancer treatment based on #MSD's #Welireg has failed a phase 3 trial, denting the company's plans to move the drug into the frontline setting.

buff.ly/xK3nzwk

Jazz and Lilly cancer drugs cleared for use by NHS Jazz's biliary tract cancer drug Ziihera and Lilly's Jaypirca for chronic lymphocytic leukaemia have been backed for NHS use in new NICE guidance.

Two therapies for #bileductcancer and #leukaemia – #JazzPharma's Ziihera and Eli Lilly's Jaypirca, respectively – have been recommended by #reimbursement agency #NICE for #NHS use.

FDA kicks off review of Roche's Gazyva for wider lupus use Roche could be just months away from an FDA approval of Gazyva as the first anti-CD20 therapy for systemic lupus erythematosus.

#Roche could be just months away from an FDA approval of #Gazyva as the first #antiCD20therapy for #systemiclupuserythematosus (SLE), a debilitating #autoimmune disease affecting millions of people around the world.

Italy leads the way on child genetic disease diagnosis A scheme to hasten the diagnosis of children with genetic disorders is achieving strong results and could be a template for national health systems.

10 years after being set up, an #Italian drive to increase #diagnosis rates in #children with #severegeneticdisorders is achieving transformative results.

pharmaphorum.com/news/italy-l...

In today’s headlines: pharmaphorum.com/news

#news #pharma #lifesciences #pharmanews #pharmaindustry

UK Knowledge Quarter welcomes Boehringer Ingelheim AI accelerator Boehringer Ingelheim has announced expansion of its global Computational Innovation footprint with a new centre dedicated to AI & ML in the UK.

#BoehringerIngelheim has announced it is expanding its global #ComputationalInnovation footprint with a new centre dedicated to #AI and machine learning (ML) in King’s Cross, #London, #UK – part of the #KnowledgeQuarter ecosystem.

#EliLilly is rumoured to be planning to spend some more of the cash raked in from its fast-growing incretin therapies for obesity and diabetes on another #acquisition, this time for #celltherapy developer #KeloniaTherapeutics.

buff.ly/Esvtlv6

AZ is three for three with COPD hope tozorakimab AstraZeneca's IL-33-targeting antibody tozorakimab has hit the target in the third of three phase 3 trials in COPD, setting up filings.

#AstraZeneca's IL-33-targeting antibody #tozorakimab has hit the target in the third of three phase 3 trials in #chronicobstructivepulmonarydisease (COPD), making a clean sweep of results and setting up #marketingapplications.

pharmaphorum.com/news/az-thre...

UCB cuts $1.15bn deal to buy epilepsy biotech Neurona UCB has dipped its toe into the M&A waters once again with an agreement to buy US biotech Neurona and its cell therapy for a common form of epilepsy.

Belgium's #UCB has dipped its toe into the M&A waters once again with an agreement to buy US biotech #NeuronaTherapeutics and its #celltherapy for #epilepsy.

pharmaphorum.com/news/ucb-cut...

Trump signs order to hasten psychedelic medicine access Donald Trump has signed an executive order directing the FDA to reduce regulatory hurdles that stand in the way of bringing psychedelics to patients.

President Donald #Trump has signed an #executiveorder directing the #FDA to reduce #regulatory hurdles that stand in the way of bringing #psychedelicmedicines for serious #mentalillness to patients.

pharmaphorum.com/news/trump-s...

When #Kailera revealed its plans for an #IPO last month, there was a feeling that it could be huge – and that expectation has now been fulfilled.

buff.ly/gZv5K8b

OpenAI introduces GPT-Rosalind, its drug discovery AI In this week's second AI model launch for life sciences research, OpenAI has introduced GPT-Rosalind, named after UK scientist Rosalind Franklin.

In this week's second major #AI model #launch for #lifesciences #research, #OpenAI has introduced #GPTRosalind, designed to accelerate #drugdiscovery and support biology-related research work.

Multiple myeloma drug Blenrep backed for wider NHS use The revitalisation of GSK's Blenrep has continued with the news that the NHS in England can use the BCMA-targeting multiple myeloma drug more widely.

The revitalisation of #GSK's #Blenrep has continued with the news that the #NHS in #England can use the #BCMAtargeting #multiplemyeloma drug more widely.

Trump names Erica Schwartz to fill leadership void at CDC Former Deputy Surgeon General Erica Schwartz could end months at the CDC without Senate-confirmed leadership if she becomes Director.

The months-long absence of permanent #leadership at the #CDC could soon be at an end, after President #Trump nominated former #DeputySurgeonGeneral Dr #EricaSchwartz as #Director of the agency.

pharmaphorum.com/news/trump-n...

UK says it has hit target on commercial trial set-up times The UK has made progress in its efforts to slash set-up times for clinical trials, one of the factors blamed for a decline in industry-backed studies.

The #UK has made progress in its efforts to slash set-up times for #clinicaltrials, one of the factors blamed for a decline in industry-backed #studies over the last few years.

Lift for UK healthtech as fund bags £100m from national bank A new Apposite Capital fund has been set up with £100m to provide much-needed scale-up funding for UK biopharma and healthtech companies.

The #BritishBusinessBank (BB) has agreed to make a £100 million #investment in a new #healthcarefund launched by London-based #privateequity group #AppositeCapital, in a boost to the #UK's #lifesciences sector.

pharmaphorum.com/news/lift-uk...

In today’s headlines: pharmaphorum.com/news

#news #pharma #lifesciences #pharmanews #pharmaindustry

The #FDA's #acceleratedapproval pathway has delivered some important new medicines to #patients more quickly, but it is plagued by inconsistencies and a lack of #transparency.

buff.ly/czOHY9W

#EliLilly says it has the #safetydata it needs to shore up the recent speedy approval of its #oralobesitytherapy #Foundayo, and also to file the GLP-1 agonist for approval in #type2diabetes later this quarter.

buff.ly/YeKBGyb

Beeline raises $300m for BMS drugs, and other biofinancings Beeline Medicines, Oricell, Terremoto, Harbinger, Neomorph, Adcendo, and STORM all closed impressive financing rounds in the last week.

The pace of #privatefinancing in #biopharma steps up again, with sizeable rounds closed by #Beeline, #Oricell, #Terremoto, #Harbinger, #Neomorph, #Adcendo, and #STORM in the last week.

pharmaphorum.com/news/beeline...

Most patients "won't see benefit" with Alzheimer's drugs A review of clinical data on amyloid-targeting Alzheimer's therapies has found absent or trivial efficacy, but is facing pushback from some experts.

A review of #clinicaldata on #amyloid beta-targeting #Alzheimer's disease therapies has concluded their #efficacy is too modest to show a clinically meaningful benefit for patients.

pharmaphorum.com/news/most-pa...

Novartis CEO joins board of "responsible" AI firm Anthropic In another signal of the deepening relationship between the pharma and AI sectors, Novartis CEO Vas Narasimhan has joined the board of Anthropic.

In another signal of the deepening relationship between the #pharma and #AI sectors, #NovartisCEO #VasNarasimhan has been appointed to the #Board of #Anthropic.

pharmaphorum.com/news/novarti...

In today’s headlines: pharmaphorum.com/news

#news #pharma #lifesciences #pharmanews #pharmaindustry